media – Page 83 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

IPhEB Russia

Organizer: IPHEB Company, Russia Date: April 8-10, 2025 Venue: Peterburgskoye sh. 64/1, St. Petersburg, Russia Exhibition hall：ExpoForum Convention and Exhibition Centre Product range: Pharmaceutical raw materials, intermediates, and formulations; antibiotic, vitamin, and amino acid-based raw materials for pharmaceuticals and veterinary drugs; Food ingredients and additives, feed additives; Pharmaceutical machinery, laboratory equipment, packaging equipment, materials, and new technologies; Contract manufacturing services, biomedical products Exhibition Introduction: The International Pharmaceutical and Healthcare Exhibition (IPhEB Russia), held in St. Petersburg, Russia, is the most influential exhibition for pharmaceutical raw materials in the country. It presents a unique opportunity for businesses in the pharmaceutical industry of Russia and the Commonwealth of Independent States (CIS) to conduct business and forge partnerships, making it the leading pharmaceutical event in the region.
- Source: drugdu
- 143
- July 10, 2024
Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital

A team of researchers is developing advanced solutions to rapidly test for drugs and improve the treatment of patients presenting to the hospital. The researchers from the Colonial Foundation Healthy Ageing Centre (Melbourne, VIC, Australia) are employing mass spectrometry technology to rapidly detect any medications or drugs that might complicate a patient’s treatment. This rapid identification is crucial to ensure that patients receive appropriate care and to minimize the effects of any previously administered medications or drugs. Mass spectrometry identifies and quantifies chemicals in a sample using charged particles, or ions, proving to be more precise than traditional immunoassays, which can sometimes yield false positives. In their recent research, published in the Medical Journal of Australia, the research team demonstrated that traditional testing methods could mistakenly show toxic levels of a heart failure medication due to interference from a common prostate cancer drug. However, when mass spectrometry was used for ...
- Source: drugdu
- 104
- July 10, 2024
Diagnostic Test Could Detect Elusive Neuro Disorder Using Tiny Drop of Spinal Fluid

Progressive supranuclear palsy (PSP) is a severe neurological disorder classified under frontotemporal dementia (FTD) that impairs cognition, movement, and behavior. Thought to be caused by an accumulation of tau proteins that damage and kill cells, PSP presents symptoms such as poor balance with frequent backward falls and difficulties moving the eyes vertically. Often misdiagnosed as Parkinson’s disease, PSP progresses more rapidly and does not respond to Parkinson’s treatments. Most individuals with PSP pass away approximately seven years after symptoms begin, and frequently, the disease is only identified posthumously during an autopsy. Unlike Alzheimer’s, there are no tau scans, blood tests, or MRIs that can conclusively diagnose PSP, a fact that has hampered the development of treatments. Now, the discovery of a unique pattern of proteins in the spinal fluid of patients could lead to earlier diagnosis and the development of new treatments for PSP. In a study published in Neurology ...
- Source: drugdu
- 102
- July 10, 2024
FDA Grants Full Approval to Johnson & Johnson’s Sirturo for Pulmonary Tuberculosis Caused by Mycobacterium Tuberculosis Resistant to Rifampicin and Isoniazid

By Don Tracy, Associate Editor Results from the Phase III STREAM Stage 2 study show the efficacy and safety of an all-oral bedaquiline-containing regimen for multidrug-resistant pulmonary tuberculosis. The FDA has granted a full approval to Johnson & Johnson’s (J&J) Sirturo for use in combination therapy in treating pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis resistant to rifampicin and isoniazid. According to the company, the approval by the FDA effectively removes previous label restrictions that were part of the medicine’s accelerated approval in December 2012. The regulatory action was based on promising results from the Phase III STREAM Stage 2 study.1 STREAM Stage 2 was the first large-scale, randomized, multi-country open-label clinical study to evaluate the efficacy and safety of an all-oral bedaquiline-containing regimen for treatment of MDR-TB. Between March 28, 2016, and January 28, 2020, 1436 participants were screened with 588 individuals randomly assigned to either the 2011 WHO ...
- Source: drugdu
- 64
- July 10, 2024
Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal

Eli Lilly’s Morphic acquisition brings an oral small molecule that blocks the same target as Entvyio, an injectable inflammatory bowel disease drug from Takeda Pharmaceutical. The Morphic deal follows Lilly’s 2023 acquisition of Dice Therapeutics, another company developing oral immunology medications. By Frank VinluanEli Lilly has immunology and inflammation products administered by injection, but the pharmaceutical giant is among the companies interested in bringing patients more convenient pill formulations. Its $3.2 billion acquisition of Morphic comes with a lead drug candidate that’s an oral small molecule in mid-stage development for inflammatory bowel disease. According to deal terms announced Monday, Lilly is paying $57 in cash for each share of Waltham, Massachusetts-based Morphic. That price represents a 79% premium to Morphic’s closing stock price on Friday. The deal, which has been approved by the boards of directors of both companies, is expected to close in the third quarter of this year. ...
- Source: drugdu
- 104
- July 10, 2024
Chiatai Tianqing’s Bicalutamide Tablets Approved

On July 5, Chiatai Tianqing received the Certificate of Drug Registration issued by State Drug Administration, approving the company’s bicalutamide tablets for the treatment of advanced prostate cancer. This is the tenth product approved by Chiatai Tianqing this year. Prostate cancer is a common malignant tumor of the male reproductive system, and it is also the second most common malignant tumor in men worldwide, with the incidence rate on the rise globally. BCC Research’s latest report pointed out that the global prostate cancer treatment market reached $35.3 billion in 2022 and is expected to grow to $56.4 billion in 2028, with a compound annual growth rate of 8.3%. . As early symptoms of prostate cancer are not easy to be detected, most patients are found in the middle to late stages. The incidence of prostate cancer is high among middle-aged and elderly men, and with the growing proportion of elderly ...
- Source: drugdu
- 75
- July 10, 2024
Sinopharm’s Quadrivalent HPV Vaccine Marketing License Application Accepted

On July 4, 2024, Sinopharm’s application for marketing authorization of quadrivalent recombinant human papillomavirus vaccine (type 6, 11, 16, 18) (Hansenula polymorpha), which was jointly declared by Sinopharm’s Chengdu Institute of Biological Products of China Biological and China Academy of Biological Sciences (National Engineering Research Center for Novel Vaccines), was accepted by the State Drug Administration under acceptance No. CXSS2400063, the first domestic quadrivalent HPV vaccine in China. This is the first quadrivalent HPV vaccine in China, which mainly covers four subtypes of HPV virus, including 6, 11, 16 and 18, and is suitable for preventive vaccination for women aged 18-45. The vaccine was independently researched and developed by China Academy of Biological Sciences and industrialized and developed by Chengdu Institute of Biological Products, and the two sides jointly conducted clinical research and initiated Phase III clinical trial in May 2018, and obtained a positive recommendation from the interim analysis ...
- Source: drugdu
- 87
- July 10, 2024
Mission awarded $5.2m to advance potential Parkinson’s treatment

The progressive neurodegenerative condition affects around 153,000 people in the UK Mission Therapeutics has been awarded $5.2m in funding from Parkinson’s UK’s Virtual Biotech programme and the Michael J. Fox Foundation to advance a potential treatment for early-stage Parkinson’s disease (PD). The funding will help support the company’s ongoing phase 1 programme, which consists of a 28-day dosing of its small drug molecule, MTX325, to assess its safety, tolerability, pharmacokinetic profile and central nervous system penetration in patients living with the neurodegenerative condition. Affecting around 153,000 people in the UK, PD is a progressive neurological condition that damages parts of the brain over time, causing tremors, slow movement and stiff and inflexible muscles. Mission’s MTX325 is a potent, selective, small-molecule brain-penetrant USP30 inhibitor that works to protect dopamine-producing neurons by improving mitochondrial quality and function. Previous research has already shown evidence that a build-up of dysfunctional mitochondria in cells is ...
- Source: drugdu
- 79
- July 10, 2024
Coloplast launches digital leakage notification system Heylo for stoma patients

More than 176,000 people in the UK are living with a stoma, according to NHS data Coloplast has announced the launch of its world-first digital leakage notification system, Heylo, to benefit patients living with a stoma. The new system is now available through the NHS to help alleviate the physical and mental burden of leakage in patients living with a stoma, following an individual consultation and assessment of leakage anxiety. According to NHS data, more than 176,000 people in the UK are living with a stoma, an opening on the abdomen that can be connected to either the digestive or urinary system to remove waste from the body. The most common conditions that can result in stoma surgery include colorectal cancer, bladder cancer, ulcerative colitis, Crohn’s disease and accidental injury. For most patients, leakage of a stoma is currently the biggest challenge, with 92% of people worrying about leakage, impacting ...
- Source: drugdu
- 66
- July 10, 2024
【EXPERT Q&A】Which reports in the medical device industry are worth paying attention to?

Drugdu.com expert’s response: In the medical device industry, there are numerous reports worthy of attention, typically issued by industry research institutions, consulting firms, or relevant government departments. These reports aim to provide comprehensive insights into the current state of the industry, market size, development trends, competitive landscape, and more. Below are some of the most noteworthy medical device industry reports: 1.Global and China Medical Device Market Research Reports Issued by: Reputable global consulting firms such as McKinsey, Boston Consulting Group , Deloitte, among others. Content Overview: These reports comprehensively cover the overall size, growth rates, market segments (including diagnostic equipment, therapeutic devices, consumables, etc.), key market drivers, regional market analyses, competitive landscapes, and future trend forecasts for both the global and Chinese medical device markets. Value: Provide industry players with a holistic view of both global and Chinese markets, facilitating the formulation of internationalization and localization strategies. 2.Medical Device Technology ...
- Source: drugdu
- 112
- July 10, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.